Stockscreener 앱 받기
12.77
8.79%
-1.23
시간 외 거래:
12.90
0.13
+1.02%
전일 마감가:
$14.00
열려 있는:
$14
하루 거래량:
616.87K
Relative Volume:
1.46
시가총액:
$203.56M
수익:
$13.11M
순이익/손실:
$-124.02M
주가수익비율:
-0.8954
EPS:
-14.261
순현금흐름:
$-107.25M
1주 성능:
-18.87%
1개월 성능:
-2.59%
6개월 성능:
-20.68%
1년 성능:
-51.63%
1일 변동 폭
$12.75
$14.01
1주일 범위
$12.75
$15.88
52주 변동 폭
$11.60
$69.97
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.77 | 223.17M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
TNXP Technical Analysis & Stock Price Forecast - Intellectia AI
Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients - Yahoo Finance
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
(TNXP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Tonix rises on commercial payer coverage for pain therapy - MSN
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 14.88% to 47.18 - MSN
TNXP stock climbs 7%: Retail bets on $30M revenue upside from Tonmya deal - MSN
Why Tonix Pharmaceuticals shares are rallying Wednesday - MSN
Tonix Pharmaceuticals Stock Jumps as Lyme Disease Antibody Data Put 2027 Trial in Focus - TechStock²
[SCHEDULE 13G/A] Tonix Pharmaceuticals Holding Corp. Amended Passive Investment Disclosure - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharma advances TNX-4800 Lyme vaccine program - TipRanks
Tonix Pharmaceuticals presents Phase 1 TNX-4800 PK data; two-dose 350mg regimen predicted to sustain 6-month protection - TradingView
Tonix (NASDAQ: TNXP) shares Phase 1 TNX-4800 Lyme prevention results - Stock Titan
Sirenia Capital and Alex Silverstein disclose 8.8% stake in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 - Sahm
Should I Buy TNXP (Tonix Pharmaceuticals Holding Corp.) | AI Analysis, Technical & News Insights - Kavout
Tonix Pharmaceuticals (TNXP) director receives 22,700-share stock option grant - Stock Titan
Tonix Pharmaceuticals (NASDAQ: TNXP) director receives 22,700 stock options grant - Stock Titan
Tonix Pharmaceuticals (NASDAQ: TNXP) director receives 22,700-share stock option grant - Stock Titan
Tonix Pharmaceuticals (TNXP) grants director 22,700 stock options - Stock Titan
Tonix Pharmaceuticals (TNXP) director receives 22,700 stock options as equity award - Stock Titan
Tonix (NASDAQ: TNXP) director receives grant of 22,700 stock options - Stock Titan
Tonix director granted options on 22,700 shares | TNXP Insider Trading - Stock Titan
Press Release: Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights - Moomoo
U.S. claims data profiles fibromyalgia patients, Tonix at ISPOR 2026 - Stock Titan
Number of shareholders of Tonix Pharmaceuticals Holding Corp. – LSX:A40VM0 - TradingView
Tonix Pharmaceuticals Holding (TNXP) Q1 Loss Deepens To US$40.2 Million Reinforcing Bearish Narratives - Sahm
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - GlobeNewswire
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
TradingKey - TradingKey
Fibromyalgia and Lyme biotech Tonix lines up two May investor talks - Stock Titan
Tonix Pharma earnings missed by $0.35, revenue fell short of estimates - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Reports Financial Update for Q1 202 - GuruFocus
Tonix Pharmaceuticals (TNXP) Reports Significant Revenue Growth in Q1 - GuruFocus
Tonix Pharmaceuticals Holding Co announced plans to initiate a Phase 2 adaptive field study of the Tnx-4800 vaccine in the United States in the first half of 2027, aiming to prevent Lyme disease. - Bitget
The US Federal Reserve's overnight reverse repurchase agreement (RRP) usage on Monday reached $1.133 billion. - Bitget
An executive from Hims & Hers Health Inc. revealed during a conference call that the company incurred approximately $33 million in restructuring expenses due to write-downs of GLP-1 related supply chain assets. - Bitget
GitLab Inc. is conducting a strategic reassessment of its global operations footprint. - Bitget
According to a document submitted to the U.S. Securities and Exchange Commission, CSG Systems International and NEC Corporation have successfully obtained approval from the Committee on Foreign Investment in the United States. Their merger transact - Bitget
On Monday (May 11), at the close in New York, S&P 500 futures rose by 0.15%, Dow Jones futures increased by 0.22%, and Nasdaq 100 futures gained 0.18%. - Bitget
Tonix Pharmaceuticals Holding Co (TNXP) announced that it expects to launch a Phase 2 clinical trial of its candidate drug Tonmya for the treatment of major depressive disorder (MDD) in the middle of this year. - Bitget
Is Tonix Pharmaceuticals (TNXP) Fairly Valued After Q1 2026 Earn - GuruFocus
BlackRock: "Fairly optimistic" about investment opportunities in Venezuela - Bitget
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):